Last reviewed · How we verify
Mixed hyperlipidemia
Approved treatments
- Inosital
Inosital works by influencing the metabolism of lipids in the body. - Niaspan · Medpointe Pharm Hlc
- Lipanor · Winthrop Pharmaceuticals UK Limited
- Ezetrol · NVP Healthcare
- Niaspan · Cedars-Sinai Medical Center
- Lescol · Novartis
Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol. - Zetia · Merck & Co.
Zetia works by blocking the absorption of cholesterol in the small intestine. - Livalo · Kowa Research Institute, Inc.
- Lipitor · Pfizer Inc.
Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. - Zocor · Merck & Co.
- Myoinositol · University of Colorado, Denver
- Nicotinic Acid · MEDPOINTE PHARM HLC
- Tricor (Micronized) · Salix
Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion. - Crestor · AstraZeneca
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor. - Lipitor · Pfizer
Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis. - Trilipix · AbbVie
- Livalo · Kowa Co
- Baycol · Bayer
- Mevacor · Merck & Co.
Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver.
Clinical guidelines
- FDA label — adj
As an adjunct to diet to reduce LDL-C and slow the progression of atherosclerosis in adults.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Mixed hyperlipidemia patent landscape — cliff calendar, originator estates, attackable patents
- Mixed hyperlipidemia treatment landscape brief
- Mixed hyperlipidemia treatment updates RSS
Frequently asked questions about Mixed hyperlipidemia
What drugs treat Mixed hyperlipidemia?
Tracked treatments include Inosital, Niaspan, Lipanor, Ezetrol, Lescol, Zetia, Livalo, Lipitor.
What is the treatment for Mixed hyperlipidemia?
Standard treatment for Mixed hyperlipidemia includes Inosital, Niaspan, Lipanor, Ezetrol, Lescol. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Mixed hyperlipidemia?
FDA label publishes guidelines for Mixed hyperlipidemia. 1 guideline references tracked.
Related
- Treatment landscape: Mixed hyperlipidemia patent cliff · Mixed hyperlipidemia CI report
- Treatment: Inosital
- Treatment: Niaspan · Medpointe Pharm Hlc
- Treatment: Lipanor · Winthrop Pharmaceuticals UK Limited
- Treatment: Ezetrol · NVP Healthcare
- Treatment: Niaspan · Cedars-Sinai Medical Center
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing